Introduction {#S5}
============

Mental disorders account for 13% of the global burden of disease, represent a significant burden of disability, and are projected to continue to rise ([@R40]). Mindfulness-based cognitive therapy (MBCT) ([@R30]), initially developed to prevent relapse or recurrence of major depressive disorder (MDD), is now being studied to treat a variety of mental health disorders. The purpose of this research was to conduct a systematic review and meta-analysis of randomised controlled trials (RCTs) assessing the efficacy and safety of MBCT for the treatment of mental disorders.

MBCT is a programme in which contemplative practices and cognitive therapy techniques are combined and delivered by MBCT-trained therapists in standard 8-week units ([@R30]). The patient visits the therapist, participates in cognitive therapy sessions, and learns mindfulness techniques, breathing and physical exercises of relaxation. Patients are coached to continue these exercises at home through recordings and notes.

The number of practitioners who use the technique is growing -- nurses, nurse practitioners, physicians, psychologists, counselors, etc. MBCT has been described in the nursing literature as an innovative approach to relieve distress for individuals suffering from medical and psychiatric illnesses ([@R26]. Priority recommendations for the implementation of the National Institute for Health and Clinical Excellence new depression guidelines include managing depression in people with physical and chronic illnesses and include using group-based cognitive-behaviour therapy ([@R21]). Nurses and advanced practice nurses interested in mental healthcare are often eager to trial novel or alternative therapeutic approaches. Evidence of efficacy, indications and specific patient populations is necessary to support implementation of therapeutic interventions.

The number of studies assessing the efficacy of MBCT is growing as well; therefore, a systematic description is needed. Systematic reviews on MBCT have been published ([@R7]; [@R8]; [@R11]; [@R19]; [@R27]). However, this review differs by including solely RCTs, by conducting sensitivity analyses on drop-out rates, and by having a different analytic strategy.

Methods {#S6}
=======

A systematic protocol was developed and implemented for this research ([@R13]).

Literature search and study selection {#S7}
-------------------------------------

In March 2011 the following databases were searched: CENTRAL, MEDLINE, EMBASE, LILACS, PsychINFO, and PsycEXTRA. The terms 'mindfulness-based cognitive therapy', 'meditation' and 'mindfulness', and 'randomised controlled trials' were used with language limit of English and Spanish. Two reviewers independently excluded reports that did not meet inclusion criteria based on title and abstract. Full published reports were obtained for the remainder, and inclusion criteria were applied. References were scanned for further RCTs.

Included studies had to: (1) be RCTs; (2) include patients with mental disorders diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders ([@R1]), the International Statistical Classification of Diseases ([@R41]) or a validated diagnostic scale; (3) deliver MBCT according to recommendations of [@R30], or with minimal adaptations made but still called MBCT by the study authors; and (4) include a change in mental health as an outcome variable.

Data abstraction {#S8}
----------------

The data were extracted independently by two reviewers and entered into data extraction forms designed for the review. Studies were assessed for methodological quality according to the Cochrane Reviewers' Handbook assessment tool ([@R35]). Disagreements between reviewers were satisfactorily resolved by discussion.

Analysis {#S9}
--------

Studies were grouped according to the type of outcome investigated and the follow-up period. In studies in which authors divided their patient populations into groups, the divisions for analysis were retained. Data obtained using the same measure and which were reported as continuous variables (or scales with a sufficient number of points to treat variables as continuous) were pooled using the weighted mean difference (WMD) with a 95% confidence interval (95% CI). When different measures were used to evaluate the same result in a comparison, data were grouped by calculating the standardised mean difference (SMD) with 95% CI. Final values were used. Dichotomous outcomes were analysed by calculating relative risk (RR) grouped in each comparison.

In order to determine whether combining the results was appropriate, *χ*^2^ and *I*^2^ tests of heterogeneity were performed. The *p*-value for *χ*^2^ was set conservatively at 0.1. *I*^2^ band values were interpreted according to the Cochrane Reviewers' Handbook ([@R35]), which recommends interpreting *I*^2^ values below 40% as non-significant heterogeneity. Subgroup analyses were done according to type of disorder, stage, co-morbidities and multifactorial interventions. The potential effect of publication bias was assessed by analysing funnel plot asymmetries when meta-analysis of at least five studies could be carried out and when no significant heterogeneity was found. To obtain more conservative estimates a random effects model for the meta-analyses was used. Finally, sensitivity analyses were conducted to explore the influence of studies with significant dropout rates (\>20%) on effect size. Results are reported according to QUOROM guidelines ([@R24]).

Results {#S10}
=======

Eleven studies meeting selection criteria were identified ([Figure 1](#F1){ref-type="fig"}). The characteristics of included studies are provided in [Table 1](#T1){ref-type="table"}. Some of the studies were reported in multiple publications. Data could not be obtained for three conference papers either because efforts to contact the authors were unsuccessful, or because authors did not supply the requested information after contacting them ([@R10]; [@R20]; [@R37]). All but one study compared MBCT to treatment as usual (TAU) ([@R29]). As a conservative approach the study reported by [@R22] was included in the MBCT + TAU versus TAU because 25% of the MBCT patients continued their medication.

[Table 2](#T2){ref-type="table"} outlines the methodological quality of included reports. Due to the nature of the intervention, double blinding cannot be implemented with interventionists. However, most studies blinded evaluators and interviewers to intervention. Allocation concealment was adequate in all of the studies. Some reports did not include all outcomes listed in methods. Therefore, there is the potential for publication bias. In the majority of the reports randomisation method was not fully described.

Effects of the intervention {#S11}
---------------------------

Meta-analyses were conducted for results including relapse rates, depression (scales were not mixed because same studies reported different scales) and anxiety (mixed scales). Stress and quality of life were reported in more than one study, but the scales for each were too distinct to standardise and combine for a meta-analysis. Other outcomes were reported with insufficient data to conduct meta-analyses. Adverse effects were not assessed in any of the studies.

### Relapse rate at 1 year post-intervention for patients with three or more previous episodes of depression {#S12}

As shown in [Figure 2](#F2){ref-type="fig"}, 430 participants contributed to this outcome. Of participants in the MBCT + TAU group 38% relapsed, compared to 62% in the TAU group. The difference between the two groups was significant in favour of MBCT + TAU (RR \[95% CI\]: 0.61 \[0.48, 0.79\]). No statistical heterogeneity was identified (*p* = 0.22, *I*^2^ = 31%). The number needed to treat to avoid a relapse was 4 (95% CI 2.6--9.1).

Subgroup analysis examined patients with MDD (≥3 episodes) in remission receiving MBCT alone or in combination with support (MBCT+) to discontinue or reduce the amount of anti-depressant medications (ADs) taken. The overall result in the MBCT alone subgroup was significant (RR \[95% CI\]: 0.55 \[0.43--0.70\]) with absence of heterogeneity (*p* = 0.45) (*I*^2^ = 0%). Results remained unchanged with sensitivity analysis (RR \[95% CI\]: 0.66 \[0.52, 0.85\]) ([Figure 3](#F3){ref-type="fig"}).

Depression measured with HAM-D at 1 year post-intervention {#S13}
----------------------------------------------------------

The Hamilton Rating Scale for Depression (HAM-D) scale ranges from 0 (minimal depression) to 53 (severe depression) ([@R15]). There is no consensus on the clinically significant difference. However, a difference of 3--3.1 points has been considered valid ([@R25]).

As shown in [Figure 4](#F4){ref-type="fig"}, 242 participants contributed to this outcome. The difference in depression mean scores between the MBCT + TAU group and the TAU group was significant in favour of MBCT + TAU (WMD \[95% CI\]: −2.46 \[−4.36 to −0.56\]). This result suggests that MBCT + TAU decreased the average degree of depression at 1-year post-intervention compared to TAU. The result of the overall *χ*^2^ test for heterogeneity was not significant (*p* = 0.99, *I*^2^ = 0%), indicating that combining these studies was appropriate.

In sensitivity analysis results did not remain stable ([Figure 5](#F5){ref-type="fig"}). While results continue to favour the MBCT + TAU group, they were no longer significant (WMD \[95% CI\]: −2.42 \[−5.40, 0.55\]). There was no statistical heterogeneity (*p* = 0.87, *I*^2^ = 0%).

Depression measured with BDI-II at 1 year post-intervention {#S14}
-----------------------------------------------------------

The Beck Depression Inventory -- second edition (BDI-II) ranges from 0 (minimal depression) to 63 (severe depression) ([@R4]), and a difference of 5 points is considered clinically relevant ([@R18]).

As shown in [Figure 6](#F6){ref-type="fig"}, 190 participants contributed to this outcome. The difference in depression mean scores between the MBCT + TAU group and the TAU group was significant in favour of MBCT + TAU (WMD \[95% CI\]: −10.39 \[−15.66 to 5.12\]). There was no statistical heterogeneity (*p* = 0.50, *I*^2^ = 0%) and findings were clinically significant. Sensitivity analysis could not be conducted due to only two studies contributing to this outcome.

Depression measured with HAM-D at post-intervention {#S15}
---------------------------------------------------

As shown in [Figure 7](#F7){ref-type="fig"}, 316 participants contributed to this outcome. The difference in depression mean scores between the MBCT + TAU group and the TAU group was significant in favour of MBCT + TAU (WMD \[95% CI\]: −4.31 \[−5.79 to −2.83\]). The result of the *χ*^2^ test for heterogeneity was not significant (*p =* 0.79, *I*^2^ = 0%). This result suggests that MBCT + TAU decreased the average degree of depression at post-intervention compared to TAU using HAM-D. Results remained stable in sensitivity analysis (WMD \[95% CI\]: −3.88 \[−6.07, −1.69\]) ([Figure 8](#F8){ref-type="fig"}).

Depression measured with BDI-II at post-intervention {#S16}
----------------------------------------------------

As shown in [Figure 9](#F9){ref-type="fig"}, 291 participants contributed to this outcome. The meta-analysis of the BDI-II scale favoured MBCT + TAU intervention: the average degree of depression decreased (WMD \[95% CI\]: −7.33 \[−12.12, −2.54\]) compared to TAU. This difference is clinically significant; however, there was statistical heterogeneity (*p =* 0.002, *I*^2^ = 73%), which cautions the appropriateness of combining the studies.

Subgroup analysis examined the effect of MBCT alone or in combination with support to discontinue or reduce the amount of ADs taken by patients with MDD (≥3 episodes) in remission or with current depression and a history of suicidal ideation. The heterogeneity of the overall effect of the meta-analysis may have been influenced by data from the first group. The likely cause of these results can be tracked by comparing the studies. Although patient profiles and interventions were similar between arms in the study conducted by [@R14] there was a significant loss of patient follow-up (22.2% in one group and 34.6% in the other), likely contributing to the gap between subgroups. The remainder of the subgroups analysed included only one study in each.

Sensitivity analysis ([Figure 10](#F10){ref-type="fig"}) excluded the study by Godfrin and van Heeringen and statistical heterogeneity disappeared (*p* = 0.20, *I*^2^ = 35%). Results remained stable (WMD \[95% CI\]: −5.68 \[−9.88, −1.49\]).

Anxiety at post-intervention {#S17}
----------------------------

As [Figure 11](#F11){ref-type="fig"} shows, 149 participants contributed to this outcome, which favoured MBCT + TAU intervention: the average degree of anxiety decreased compared to TAU (SMD \[95% CI\]: −0.42 \[−0.74, −0.09\]). The result of the tests for heterogeneity were not significant (*p* = 0.55, *I*^2^ = 0%). Anxiety was measured with different scales in each of the studies ([@R12]; [@R38]. Because patients are heterogeneous, differences may be due to subgroup differences rather than to the use of different scales.

Evaluation of publication bias {#S18}
------------------------------

Funnel plots ([Figures 12](#F12){ref-type="fig"} and [13](#F13){ref-type="fig"}) do not show major asymmetry, indicating that there is no clear evidence of publication bias. However, due to the low number of studies this bias could not be assessed for all outcomes.

Discussion {#S19}
==========

The main results indicate that MBCT + TAU are more effective at preventing episodes or prolonging time between episodes of depression than TAU alone. Patients with recurrent depression (≥3 episodes) treated with MBCT + TAU have on average 40% fewer relapses compared to patients undergoing TAU alone. One relapse is avoided for every four patients treated with MBCT in comparison to those receiving TAU. This effect is statistically significant and remained stable under sensitivity analysis. Given that MBCT teaches techniques that should be practiced on a daily basis to maintain its effectiveness over time, long-term studies are particularly important. Rate of relapse was the primary outcome of the majority of the studies identified and included in this systematic review and meta-analysis; therefore sample sizes were calculated for relapse rates giving methodological robustness to our findings. Furthermore, a relapse rate is a more robust and objective measure compared to self-reported measures. Depressive symptoms at 1 year post-intervention measured by HAM-D and BDI-II scales were statistically significant (and clinically significant at least in the case of HAM-D), but did not remain stable. New trials with adequate methodological quality are needed to further evaluate this outcome.

Unsurprisingly, the results of the meta-analysis of individuals who had two previous episodes of depression at one year of follow-up (data not demonstrated) showed no significant differences. The particular difference in the number of previous episodes of depression is supported by the hypothesis of differential activation ([@R32]). This hypothesis states that with each new relapse in depression the strength of the association between negative mood and dysfunctional patterns of thought and rumination increases in such a way that every time it is less necessary for a stressful stimulus to reproduce the relapse.

In a recent study that could not be meta-analysed because of the unique comparison groups, recurrently (\>1 episode) depressed patients in remission were randomised to receive ADs, MBCT plus a discontinuation of ADs, or placebo instead of ADs ([@R29]). After 18 months of follow-up results showed that among unstable remitters, patients in both MBCT and ADs showed a 73% decrease in hazard of relapse compared with placebo (*p* = 0.03). In contrast, stable remitters showed no differences. These results suggest that MBCT offers protection against relapse on par with that of maintenance AD pharmacotherapy. This was the most important result with intent-to-treat or available case analysis among the reported studies that could not be meta-analysed.

Other significant single RCT results with intent-to-treat or available case analysis at one year of follow-up comparing MBCT to TAU include a reduction in the number of diagnosed psychiatric co-morbidities ([@R22]), a reduction of depressive symptoms and anger, an increase of strength and an improvement in the quality of life ([@R12]; [@R14]). MBCT was also shown to do as well as group cognitive therapy in decreasing social phobia symptoms ([@R28]). However, there were no significant differences for the use of ADs ([@R34]), the amount, duration, severity and degree of distress of relapses, quality of life measured by the OMS scale, the total cost of treatment per year during the year of follow-up ([@R22]), and fatigue and tension ([@R14]). The remainder of the results included in this systematic review had shorter or no follow-up periods so it is uncertain whether the results are maintained over time.

MBCT has been predominantly implemented for depressive patients. However, as seen in medical, nursing, and other arenas involved in mental healthcare, depression is a symptom that is present in many psychiatric and psychological conditions; therefore, the theoretical foundations of MBCT are relevant to the whole spectrum of mental health pathologies. Moreover, depression is highly prevalent in patients with physical illness and in aging populations. The populations analysed in most studies included in this review suffered from serious and recurrent depression. More RCTs to evaluate the intervention in populations with less severity are needed.

Comparing results with other reviews {#S20}
------------------------------------

Two systematic reviews on MBCT RCT's without meta-analyses were published before ([@R8]; [@R11]). Findings in the current study agree with [@R8] and [@R11] in highlighting that because of the nature of the control groups results cannot be attributed to specific effects of MBCT. More clinical studies with long-term follow-up are needed to better understand and confirm specific effects of MBCT. Problems which can surface when traditional statistical analyses are applied to interventions in which groups are used were also pointed out previously ([@R38]. Groups of patients are able to influence each other's outcomes and thus variables are no longer necessarily independent.

A systematic review and meta-analysis on MBCT was recently published ([@R7]) in which non-randomised trials were included and more conservative analyses were conducted by presenting diagnostic subgroup analyses only. Nonetheless, in spite of the differences between Chiesa's work and the current review, the main conclusions are similar.

[@R27] published another systematic review on MBCT that included patients with MDD only. Their findings on relapse prevention were similar to those of this review, but they added a meta-analysis including MDD patients with any number of episodes and the results were significant (RR = 0.66 for MBCT compared to treatment as usual or placebo controls). Other differences with this review are that Piet and Hougaard were less conservative when including Kuyken et al.'s study in a meta-analysis comparing MBCT against ADs (yet getting not significant results), that they did not have a previous formal protocol, that they did not use the Cochrane tool to assess the methodological quality of the studies, and that they did not explore drop-out rates in sensitivity analyses. [@R27] made a final remark we found interesting: that it may be premature to exclude patients with 2 MDD relapses from future studies since not enough data have been collected.

A meta-analytic review was published ([@R19]) on the effect of mindfulness-based therapies on depression and anxiety, obtaining moderate effect sizes. However, as this analysis is pre-post and uncontrolled, the validity of the results is much lower than that of meta-analyses of RCTs, such as those presented in this review.

Limitations {#S21}
-----------

Important limitations of the current review are the low number of studies in the meta-analyses and the fact that only dichotomous variables were used to measure relapse rates. In addition, mental health problems are chronic or long-term conditions but outcomes were not reported to assess long-term effects beyond the first year of follow-up.

Although participants in all the reported studies were depressed or had been depressed in the past, the heterogeneity among studies was high. To counter this limitation subgroup analyses were conducted. Although this study was performed as per the version of the Cochrane Handbook available at the time, a new version is now in place ([@R36]). The most relevant update concerning this review is that the risk of bias table was slightly expanded. Finally, the search strategy used to support this review was thorough. However, grey literature data could have been further assessed through contacting key informants.

Despite these limitations it is concluded that MBCT is an effective tool at least for patients with three or more previous episodes of major depression.
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###### 

Characteristics of included studies.

  Study no.   Publication                      Type               No.   MBCT duration   Follow-up   Location                Ages[a](#TFN1){ref-type="table-fn"}   Patients                                                                                                                Experimental group                           Control groups                          Primary outcomes                                                                             Secondary outcomes
  ----------- -------------------------------- ------------------ ----- --------------- ----------- ----------------------- ------------------------------------- ----------------------------------------------------------------------------------------------------------------------- -------------------------------------------- --------------------------------------- -------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  1           [@R34], [@R33]; [@R39], [@R38]   RCT multi-center   145   8 weeks         1 yr        Great Britain, Canada   18--65                                Patients with MD (≥2 episodes) in remission                                                                             MBCT + TAU                                   TAU                                     Relapse that meets DSM-III criteria for MD                                                   BDI II, MACAM, use of AD, type of memory
  2           [@R23]; [@R38]                   RCT                75    8 weeks         1 yr        Great Britain           18--65                                Patients with (≥MD 2 episodes) in remission                                                                             MBCT + TAU                                   TAU                                     Relapse that meets DSM-III --R criteria for MD                                               BDI II
  3           [@R22]                           RCT                123   8 weeks         1 yr        Great Britain           ≥18                                   Patients with MD (≥3 episodes) in remission, taking ADs                                                                 MBCT +support to discontinue or reduce ADs   Maintenance ADs                         Relapse that meets DSM-III criteria for MD                                                   Characteristics of relapses, BDI II, HAM-D, psychiatric co-morbidities, WHOQOL-BREF, cost
  4           [@R3]; [@R9]; [@R17]; [@R38]     RCT                68    8 weeks         1 yr        Great Britain           18--65                                Bipolar and unipolar patients with MD (≥1 episode) in remission with suicidal ideation                                  MBCT + TAU                                   TAU                                     Prefrontal alpha-asymmetry during sleep EEG, BDI II, BAI, White Bear Suppression Inventory   
  5           [@R14]                           RCT                106   8 weeks         1 yr        Belgium                 ≥18                                   Patients with MD (≥3 episodes) in remission                                                                             MBCT + TAU                                   TAU                                     Relapse that meets DSM-IV-TR criteria for MD                                                 BDI II, HAM-D, POMS, QLDS
  6           [@R5]                            RCT                60    8 weeks         1 yr        Switzerland             18--65                                Patients with MD (≥3 episodes) in remission                                                                             MBCT + TAU                                   TAU                                     Relapse that meets DSM-IV criteria for MD                                                    BDI II, frequency of practice of full attention during the study
  7           [@R2]; [@R16]                    RCT                31    8 weeks         absent      Great Britain           18--65                                Patients with MD (≥3 episodes) with suicidal ideation                                                                   MBCT + TAU                                   TAU                                     Relapse that meets DSM-IV criteria for MD                                                    BDI II and Beck scale for sucicidal ideation
  8           [@R12]                           RCT                115   8 weeks         12 weeks    Australia               ≥18                                   Oncology patients with depression                                                                                       MBCT + TAU                                   TAU                                     HAM-D, HAM-A, DASS, (FACT--G)                                                                Frieburg Mindfulness Inventory
  9           [@R28]                           RCT crossover      26    8 weeks         1 yr        Denmark                 18--25                                Patients with social phobia                                                                                             MBCT                                         GCBT                                    LSAS, SPS and SIAS                                                                           SPC,SCL-90-R, Symptom Checklist- 90-Revised, IPP, FNE, SDS, BDI II, BAI
  10          [@R6]; [@R31]                    RCT                26    8 weeks         absent      USA                     24--64                                Antidepressant-free individuals with partial or totally remission of DM (≥3 episodes), with residual sleep complaints   MBCT + TAU                                   TAU                                     Polysomnographic sleep profiles                                                              BDI II, sleep diaries
  11          [@R29]                           RCT                84    8 weeks         18 months   Canada                  18--65                                Patients with MD (≥2 episodes) in remission                                                                             MBCT + support to discontinue ADs            2 groups: Placebo and maintenance ADs   Time to relapse/recurrence of DM                                                             --

Male and female patients.

Yr: year; RCT: randomised controlled trial; MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; DM: major depression; BDI: Beck depression inventory; MACAM: measure of awareness and coping in autobiographical memory; AD: antidepressants; HAM-D: Hamilton rating scale for depression; WHOQOL-BREF: World Health Organization Quality of Life instrument; EEG: electroencephalogram; BAI: Beck anxiety inventory; POMS: profile of moods scale; QLDS: quality of life in depression scale; HAM-A: Hamilton anxiety rating scale; DASS: depression, anxiety stress scale; FACT-G: functional assessment of cancer therapy-general; GCBT: group cognitive-behavioural therapy; SPC: social phobia composite; SPS: social phobia scale; SIAS: social interaction scale; LSAS: Liebowitz social anxiety scale; SCL-90-R: symptom checklist-90-revised; IPP: inventory of interpersonal problems; FNE: fear of negative evaluation; SDS: Shehan disability scale.

###### 

Risk of bias table.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study no.   Appropriate randomisation method?   Concealment of allocation?   Blinding?                                                    Free selective reporting of outcomes?                                                                                         Loss to follow-up treated correctly?                                                                                                                                                              Free of other biases?
  ----------- ----------------------------------- ---------------------------- ------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------
  1           Unclear                             Yes                          No\                                                          No\                                                                                                                           Unclear\                                                                                                                                                                                          Unclear\
                                                                               Evaluation of results was blinded                            Some of the data collected were not available (BDI II: not reported in [@R34] and partially reported in [@R38]                Loss to follow-up was low and balanced between groups (3% in TAU and 5% in MBCT + TAU), but did not provide the reasons for the losses                                                            Contamination bias evaluation due to group intervention was not significant. Co-morbidities were taken into consideration, ITT analysis was conducted

  2           Unclear                             Yes                          No\                                                          Yes                                                                                                                           Unclear\                                                                                                                                                                                          Unclear\
                                                                               Evaluation of results was blinded                                                                                                                                                          Loss to follow-up was low and balanced between groups (2.6% in TAU and 2.7% in MBCT + TAU), reasons for to loss follow-up not described                                                           Contamination bias evaluation due to group intervention was not significant. Co-morbidities were taken into consideration, ITT analysis was conducted

  3           Yes                                 Yes                          No\                                                          Yes                                                                                                                           Unclear\                                                                                                                                                                                          Unclear\
                                                                               Reviewers were blinded to group allocation                                                                                                                                                 Loss to follow-up was low (9.7% in TAU and 3.3% in MBCT + TAU), but groups were not balanced and the reasons for the losses were only partially explained                                         Contamination bias evaluation due to group intervention was not significant. Co-morbidities were taken into consideration, ITT analysis was conducted

  4           Unclear                             Yes                          No\                                                          No\                                                                                                                           Unclear\                                                                                                                                                                                          No\
                                                                               Reviewers were blinded to group allocation                   Some results of interest were incompletely reported and could not be included in the meta-analysis (ITT analysis in [@R9])    Loss to follow-up was high (34% in TAU and 9% in MBCT + TAU for some results, 15% in TAU and 23% in MBCT + TAU for [@R38] results), and reasons for the losses were not described                 ITT analysis unspecified (e.g. [@R17]) or partially reported (e.g. [@R9])

  5           Yes                                 Yes                          No\                                                          Yes                                                                                                                           Unclear\                                                                                                                                                                                          No\
                                                                               No blinding                                                                                                                                                                                Loss to follow-up was high (22.2% TAU and 34.6% MBCT + TAU), and reasons for the losses were only partially explained                                                                             ITT analysis was conducted but loss to follow-up was high and authors did not specify how missing data were dealt with. Co-morbidities were taken into consideration

  6           Unclear                             Yes                          No\                                                          Yes\                                                                                                                          Unclear\                                                                                                                                                                                          Unclear\
                                                                               Raters were blinded to group allocation                      Not all outcomes pre-specified in the methods section were reported. Authors did provide missing data after being contacted   Loss to follow-up was low (3.4% TAU and 12.9% in MBCT + TAU), but reasons for the losses were not described                                                                                       Co-morbidities were taken into consideration, ITT analysis was conducted

  7           Yes                                 Yes                          No\                                                          Yes                                                                                                                           Unclear\                                                                                                                                                                                          Unclear\
                                                                               Reviewers were blinded to group allocation                                                                                                                                                 Loss to follow-up was low (6.7% TAU and 12.5% in MBCT + TAU), but reasons for the losses were not described. Final data from lost participants were imputed by carrying forward baseline data     Co-morbidities were taken into consideration, ITT analysis was conducted

  8           Yes                                 Yes                          No\                                                          Yes                                                                                                                           Unclear\                                                                                                                                                                                          Unclear\
                                                                               Reviewers were blinded to group allocation                                                                                                                                                 Loss to follow-up was moderate (16.7% TAU and 10.9% in MBCT + TAU), but reasons were only partially explained. Final data from lost participants were imputed by carrying forward baseline data   Co-morbidities were taken into consideration, ITT analysis was conducted

  9           Unclear                             Yes                          No                                                           Yes\                                                                                                                          Yes\                                                                                                                                                                                              Unclear\
                                                                                                                                            All outcomes pre-specified in the methods section were reported                                                               Loss to follow-up losses was high (21.4% in MBCT and 8.3% in GCBT) and reasons for the losses were provided                                                                                       Co-morbidities were taken into consideration, ITT analysis was conducted

  10          Unclear                             Yes                          No\                                                          Yes\                                                                                                                          Unclear\                                                                                                                                                                                          No\
                                                                               Researchers who collected Post- baseline data were blinded   All outcomes pre-specified in the methods section were reported                                                               Loss to follow-up was moderate (17.4% in TAU and 10.3% in MBCT) and reasons for losses were partially reported                                                                                    No ITT analysis

  11          Yes                                 Yes                          No\                                                          No\                                                                                                                           No\                                                                                                                                                                                               Unclear\
                                                                               Evaluators blinded to treatment allocation                   Some of the secondary outcomes stated in the methods section are not reported                                                 Loss to follow-up was high (25% in AD, 20% in placebo and 19.2% in MBCT), reasons for the losses were provided                                                                                    Co-morbidities were taken into consideration, ITT analysis was conducted
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MBCT: mindfulness-based cognitive therapy; TAU: treatment as usual; BDI: Beck depression inventory; ITT: intention to treat; GCBT: group cognitive-behavioural therapy; AD: maintenance antidepressants group.

###### Implications for practice

With increasing use of MBCT across a range of practitioners, the clinical relevance of MBCT can be considered. Findings from this systematic meta-analysis can be used to inform nurses and other mental health practitioners on the efficacy, patient population and type of mental illnesses which best respond to MBCT technique based on findings from randomised control trials.

###### Key points for policy, practice and research

-   Patients with recurrent depression (three episodes or more) treated with additive MBCT have on average 40% fewer relapses at one year of follow-up compared to patients undergoing treatment as usual.

-   Improvements in depression and anxiety with additive MBCT were significant at one year of follow-up but unstable in sensitivity analyses.

-   More studies with active control groups and long-term follow-ups are needed to better understand the specific effects of MBCT.

-   Depression is a symptom that is present in many conditions. More high quality RCTs are needed to evaluate MBCT in populations with varying depression severity as well as diagnosis with multiple co-morbidities.
